Concepedia
Statistics
Publications
4
Citations
83
H-Index
Active since
2015
Affiliations
KU Leuven(Current)
Boehringer Ingelheim (Belgium)
Institut Jules Bordet
Université Libre de Bruxelles
Boehringer Ingelheim (Germany)
Jo Costermans is an author at KU Leuven specializing in toxicity management, oncology, and pharmacokinetics of anticancer drugs.
Publications per year
2015–2019
Phase I trial of volasertib, a Polo-like kinase inhibitor, plus platinum agents in solid tumors: safety, pharmacokinetics and activity
Ahmad Awada, Herlinde Dumez, Philippe Aftimos et al. · Investigational New Drugs · 2015 · 30 citations · Full text
Pharmacy, Oncology, Pharmacokinetics +17
A phase I study of two dosing schedules of oral BI 847325 in patients with advanced solid tumors
Patrick Schöffski, Philippe Aftimos, Herlinde Dumez et al. · Cancer Chemotherapy and Pharmacology · 2015 · 18 citations
Pharmacy, Oncology, Pharmacokinetics +11
Phase I first-in-man trial of a novel bromodomain and extra-terminal domain (BET) inhibitor (BI 894999) in patients (Pts) with advanced solid tumors.
Philippe Aftimos, Oliver Bechter, Ahmad Awada et al. · Journal of Clinical Oncology · 2017 · 18 citations
Medicine, Oncology, Pharmacology +13
A phase I dose-finding and pharmacokinetics study of CPC634 (nanoparticle entrapped docetaxel) in patients with advanced solid tumors.
Florence Atrafi, Herlinde Dumez, Ron H.J. Mathijssen et al. · Journal of Clinical Oncology · 2019 · 17 citations
Pharmacy, Pharmacokinetics, Pharmacology +17
1–4 of 4